Combination treatment of pancreatic cancer

US11351156B2 · kind B2 · utility

Assignees

• INSERM · FR
• UNIVERSITE PAUL SABATIER—TOULOUSE III · FR
• C.N.R.S. · FR
• KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN · DE

Inventors

• Julie Guillermet-Guibert · Toulouse, FR
• Maximillian Reichert · Munich, DE
• Celia Cintas · Nairobi, KE

Key dates

• Filing date: Oct 12, 2018
• Grant date: Jun 7, 2022
• Expiry date: Oct 12, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. The inventors questioned this concept, by mapping differential isoform-specific downstream signalling in response to their constant selective inhibition in pancreatic cancer, a disease currently without therapy. They identified common and specific signals activated by each PI3K isoform. These data make the rational for the development of highly selective PI3K isoform drugs used in combination, instead of compounds inhibiting all PI3Ks. In particular, the inventors showed that combined p110a and 110γ inhibition is the most efficient strategy for pancreatic cancer patients.